APVO.NASDAQAptevo Therapeutics INC

8-K: Aptevo Therapeutics Files Prospectus Supplement for $3.17 Million Common Stock Offering

Sentiment:

Current Report

📋All filings for Aptevo Therapeutics INC
🔒Login to Follow

Aptevo Therapeutics has filed a prospectus supplement with the SEC to offer and sell up to $3.17 million of its common stock under an existing 'at-the-market' offering agreement.

Capital raiseAptevo Therapeutics is offering up to $3,167,548 of its common stock through an 'at-the-market' offering.The offering will be conducted through Roth Capital Partners, LLC, as sales agent.The company had previously sold 305,845 shares for $181,848 under the same agreement.

Summary

  • Aptevo Therapeutics Inc. filed a prospectus supplement with the SEC on April 29, 2025, relating to the offer and sale of its common stock.
  • The aggregate offering price is up to $3,167,548.
  • The shares will be offered under the existing At The Market Offering Agreement with Roth Capital Partners, LLC, as sales agent.
  • As of the date of the Prospectus Supplement, the Company had issued and sold 305,845 shares of its Common Stock at an aggregate gross offering price of $0.5946 pursuant to the Sales Agreement and the Prior Prospectus Supplement and accompanying base prospectus for aggregate gross sale proceeds of $181,848.
  • The offering is registered under Form S-3 (File No. 333-284969).
  • Paul Hastings LLP has issued a legal opinion relating to the shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard announcement of a stock offering. The offering itself could be seen as a positive (raising capital) or a negative (diluting existing shares), depending on the investor's perspective.

Future Outlook

The company intends to offer and sell shares of its common stock from time to time.

Industry Context

Many small biotech companies use 'at-the-market' offerings to raise capital, which can be more flexible than traditional underwritten offerings.

Stakeholder Impact

  • Shareholders may experience dilution due to the issuance of new shares.
  • The company will have additional capital to fund its operations.

Next Steps

  • Aptevo will continue to offer and sell shares of its common stock through Roth Capital Partners, LLC.
  • The company will use the proceeds from the offering for general corporate purposes.

Key Dates

DateDescription
March 26, 2020Amended and Restated Certificate of Incorporation of the Company (as amended).
March 5, 2024Amended and Restated Certificate of Incorporation of the Company (as amended).
December 3, 2024Amended and Restated Certificate of Incorporation of the Company (as amended).
February 14, 2025Company filed Registration Statement on Form S-3 (File No. 333-284969) with the SEC.
February 26, 2025Registration Statement declared effective by the Commission.
February 26, 2025Base prospectus date.
April 28, 2025Date of the Sales Agreement between Aptevo and Roth Capital Partners.
April 28, 2025Initial Prospectus Supplement date.
April 28, 2025Company filed prospectus supplement with the SEC pursuant to Rule 424(b) under the Act.
April 29, 2025Date of Report (Date of earliest event reported).
April 29, 2025Subsequent Prospectus Supplement date.
April 29, 2025Company filed prospectus supplement with the SEC pursuant to Rule 424(b) under the Act.

Keywords

Aptevo Therapeutics, common stock, offering, prospectus supplement, Roth Capital Partners, securities, SEC, ATM offering

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.